Regeneron Pharmaceuticals (REGN)
(Delayed Data from NSDQ)
$1,012.82 USD
-1.77 (-0.17%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1,012.36 -0.46 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1,012.82 USD
-1.77 (-0.17%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1,012.36 -0.46 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Zacks News
Kodiak Sciences (KOD) Q1 Loss Widens, Eye Candidate in Focus
by Zacks Equity Research
Kodiak Sciences (KOD) reports wider-than-expected loss in the first quarter of 2022. Focus is on lead candidate, KSI-301, being developed for treating various retinal vascular diseases.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the first quarter of 2022.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Intellia (NTLA) Q1 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Intellia Therapeutics (NTLA) posts wider-than-expected Q1 loss while sales beat the mark. NTLA continues to advance its pipeline with developmental programs.
Ultragenyx's (RARE) Q1 Earnings & Revenues Miss Estimates
by Zacks Equity Research
Ultragenyx (RARE) reports wider-than-expected loss in the first quarter of 2022 while revenues miss estimates.
Regeneron (REGN) Q1 Earnings Beat, COVID Antibody Sales Affected
by Zacks Equity Research
Regeneron (REGN) beats on Q1 earnings and sales record year-over-year growth on the solid performance of Dupixent and Eylea.
Regeneron (REGN) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 22.63% and 9.47%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Will Eylea, Dupixent Buoy Regeneron's (REGN) Q1 Earnings?
by Zacks Equity Research
Regeneron's (REGN) first-quarter performance might have gotten a boost from the solid performance of Eylea and Dupixent.
The Zacks Analyst Blog Highlights Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen
by Zacks Equity Research
Novo Nordisk, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and Biogen have been included in this Analyst Blog.
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Alnylam (ALNY) Misses on Q1 Earnings, Lowers '22 Revenue View
by Zacks Equity Research
Alnylam's (ALNY) earnings and sales fall shy of estimates in the first quarter of 2022. The company cuts 2022 guidance for net product revenues. Shares down.
5 Big Pharma, Biotech Stocks Set to Beat Q1 Earnings Estimates
by Indrajit Bandyopadhyay
Let us take a look at some pharma/biotech stocks, REGN, BIIB, NVO, VRTX and MRNA that are poised to beat on first-quarter earnings.
Sanofi (SNY) Q1 Earnings Top, Vaccines Recover, CHC Sales Rise
by Zacks Equity Research
Sanofi (SNY) beats first-quarter estimates for earnings and sales. Dupixent drives sales growth along with strong recovery in travel vaccines. Consumer healthcare sales remain strong.
Should You Invest in the First Trust Health Care AlphaDEX ETF (FXH)?
by Zacks Equity Research
Sector ETF report for FXH
Regeneron (REGN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Regeneron (REGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Regeneron (REGN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $690.33 in the latest trading session, marking a +0.33% move from the prior day.
Roche's (RHHBY) Q1 Sales Grow on COVID-19 Tests, New Drugs
by Zacks Equity Research
Roche (RHHBY) performance in the first quarter was encouraging, driven by demand for COVID-19 tests and contribution from newer drugs.
Regeneron (REGN) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Regeneron (REGN) closed at $706.11 in the latest trading session, marking a -1.88% move from the prior day.
Biotech Stock Roundup: NKTR Plunges on Deal Termination, REGN Offers Update & More
by Zacks Equity Research
Regulatory and pipeline updates from Nektar (NKTR) and Regeneron (REGN) are a few key highlights from the biotech sector during the past week.
Regeneron (REGN) to Buy Checkmate Pharmaceuticals for $250M
by Zacks Equity Research
Regeneron (REGN) is set to acquire Checkmate Pharmaceuticals for $250 million to broaden its portfolio of diverse immuno-oncology candidates.
Amgen's (AMGN) Stelara Biosimilar Meets Psoriasis Study Goal
by Zacks Equity Research
Initial data from a late-stage study comparing Amgen's (AMGN) Stelara biosimilar candidate with the original Stelara drug showed no clinically meaningful differences in treating plaque psoriasis.
Regeneron (REGN) REGEN-COV BLA Review Extended by 3 Months
by Zacks Equity Research
Regeneron (REGN) biologics license application for antibody cocktail REGEN-COV (casirivimab and imdevimab) gets a three-month FDA extension.
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
by Zacks Equity Research
Regeneron (REGN) gains 17% YTD on the back of Eylea, Dupixent and good pipeline progress.
Zacks Investment Ideas feature highlights: Regeneron and Bristol-Myers Squibb
by Zacks Equity Research
Regeneron and Bristol-Myers Squibb are part of today's Investment Idea article.